loading page

Promising Effects of Atorvastatin on Outcomes of Patients with Severe COVID-19, A Retrospective Cohort Study
  • +5
  • Mohmmad Haji Aghajani,
  • Omid Moradi,
  • Hamed Azhdari Tehrani,
  • Hossein Amini,
  • Elham Pourheidar,
  • Firouze Hatami,
  • Mohammad Mahdi Rabiei,
  • Mohammad Sistanizad
Mohmmad Haji Aghajani
Shahid Beheshti University of Medical Sciences
Author Profile
Omid Moradi
Author Profile
Hamed Azhdari Tehrani
Shahid Beheshti University of Medical Sciences
Author Profile
Hossein Amini
Shahid Beheshti University of Medical Sciences
Author Profile
Elham Pourheidar
Shahid Beheshti University of Medical Sciences
Author Profile
Firouze Hatami
Shahid Beheshti University of Medical Sciences
Author Profile
Mohammad Mahdi Rabiei
Shahid Beheshti University of Medical Sciences
Author Profile
Mohammad Sistanizad
Shahid Beheshti University of Medical Sciences
Author Profile

Abstract

Purpose: Considering the anti-inflammatory effect of atorvastatin and the role of medical comorbidities such as hypertension and coronary artery disease on prognosis of the COVID-19 patients, we aimed to assess the effect of atorvastatin add-on therapy on mortality due to COVID-19. Methods: We conducted a retrospective cohort study, including patients who were hospitalized with confirmed diagnosis of severe COVID-19. Baseline characteristics and related clinical data of patients were recorded. Clinical outcomes consist of in hospital mortality, need for invasive mechanical ventilation and hospital length of stay. COX regression analysis models were used to assess the association of independent factors to outcomes. Results: Atorvastatin was administered for 421 out of 991 patients. The mean age was 61.640±17.003 years. Older age, higher prevalence of hypertension and coronary artery disease reported in patients who received atorvastatin. These patients had shorter hospital length of stay (P=0.001). Based on COX proportional hazard model, in hospital use of atorvastatin was associated to decrease in mortality (HR=0.679, P=0.005) and lower need for invasive mechanical ventilation (HR=0.602, P=0.014). Conclusions: Atorvastatin add-on therapy in patient with severe COVID-19 was associated with lower in hospital mortality and reduced the risk of need for invasive mechanical ventilation which support to continue the prescription of the medication.

Peer review status:ACCEPTED

09 Feb 2021Submitted to International Journal of Clinical Practice
13 Feb 2021Submission Checks Completed
13 Feb 2021Assigned to Editor
16 Feb 2021Reviewer(s) Assigned
26 Mar 2021Review(s) Completed, Editorial Evaluation Pending
29 Mar 20211st Revision Received
29 Mar 2021Assigned to Editor
29 Mar 2021Submission Checks Completed
31 Mar 2021Reviewer(s) Assigned
06 Apr 2021Review(s) Completed, Editorial Evaluation Pending
03 May 20212nd Revision Received
07 May 2021Review(s) Completed, Editorial Evaluation Pending
07 May 2021Submission Checks Completed
07 May 2021Assigned to Editor
08 May 2021Reviewer(s) Assigned
28 May 2021Editorial Decision: Accept